Open AccessP1105: FINAL RESULTS OF THE PHASE I/II HOVON124/ECWM‐R2 STUDY INCLUDING 2‐YEAR RITUXIMAB MAINTENANCE AFTER INDUCTION WITH IXAZOMIB, RITUXIMAB AND DEXAMETHASONE IN RELAPSED WALDENSTRÖM'S MACROGLOBULINEMIA
Author(s) -
Dimopoulos M.A.,
Amaador K.,
Minnema M. C.,
Nasserinejad K.,
Kap M.,
Kastritis E.,
Gavriatopoulou M.,
Kraan W.,
Chamuleau M. E. D.,
Deeren D.,
Tick L.,
Doorduijn J. K.,
Offner F.,
Böhmer L. H.,
Liu R. D.,
Pals S. T.,
Vos J. M.,
Kersten M. J.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000847288.62394.e8
Subject(s) - rituximab , medicine , maintenance therapy , dexamethasone , neutropenia , surgery , clinical endpoint , macroglobulinemia , phases of clinical research , gastroenterology , median follow up , toxicity , multiple myeloma , clinical trial , chemotherapy , lymphoma